Modified antibodies which are motifs that contain cysteine residues linked, modified antibody comprising the modified antibodies - drug conjugate and a method of manufacturing
The present invention relates to an antibody in which a motif consisting of an amino acid or peptide containing one or more cysteine residues is bound to the end of a parent antibody, particularly to the end of a heavy chain, and a modified antibody in which such an antibody is bound to a drug. The present invention relates to a drug conjugate (mADC) and a method for producing the antibody or modified antibody-drug conjugate. The modified antibody-drug conjugate (mADC, Anti-Drug Conjugate) according to the present invention can accurately deliver the drug to the target cells due to the high specificity of the antibody contained in the complex to the antigen, thereby enhancing the therapeutic effect. Moreover, it is possible to improve the utilization of drugs whose use is restricted due to toxicity despite high effects, particularly anticancer agents. The present invention also relates to a composition for treating diseases, particularly cancer, using the modified antibody-drug complex.本発明は、一つ以上のシステイン残基を含んだアミノ酸またはペプチドからなるモチーフ（motif）が親抗体の末端、特に重鎖末端に結合した抗体、そのような抗体と薬物が結合した修飾抗体－薬物複合体（ｍＡＤＣ、Antibody-Drug Conjugate）及び前記抗体または修飾抗体－薬物複合体の製造方法に関する。本発明に係る修飾抗体－薬物複合体（ｍＡＤＣ、Antibody-Drug Conjugate）は、複合体に含まれた抗体の抗原に対する高い特異性によりターゲット細胞に薬物を正確に伝達できて、治療効果が高められ、また高い効果にもかかわらず毒性により使用が制限的な薬物、特に抗癌剤などの活用度を向上することができる。また、本発明は前記修飾抗体－薬物複合体を利用した疾病、特に癌の治療用組成物に関する。
